NDAORALTABLET
Approved
Sep 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
CLINORIL (sulindac) by Merck & Co. is clinical pharmacology pharmacodynamics sulindac is a non-steroidal anti-inflammatory drug (nsaid) that exhibits anti-inflammatory, analgesic and antipyretic activities in animal models. First approved in 1978.
Drug data last refreshed 13h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLINORIL (sulindac) is an oral NSAID tablet approved in 1978 that exhibits anti-inflammatory, analgesic, and antipyretic activities, likely through prostaglandin synthetase inhibition. The drug is absorbed orally with a Tmax of 3-7 hours and undergoes hepatic metabolism to active and inactive metabolites with extensive enterohepatic circulation.
LOE Approaching
CLINORIL is approaching loss of exclusivity with moderate competitive pressure (30), indicating a mature product in transition phase likely with reduced headcount and focus on generic transition management.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Sulindac is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic activities in animal models. The mechanism of action, like that of other NSAIDs, is not completely understood but may be related to…
Worked on CLINORIL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.